[September 12, 2014]

Research and Markets: Global Glomerulonephritis Therapeutics Pipeline Review 2014: 6 Companies & 8 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/mf8g9h/glomerulonephritis) has announced the addition of the "Glomerulonephritis - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured nes and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Cyclacel Pharmaceuticals, Inc.
• Toray Industries, Inc.
• Hansa Medical AB
• Pharmalink AB
• Avexxin AS
• FibroStatin SL

Drug Profiles

• budesonide
• CYC-065
• Endoglycosidase of Streptococcus pyogenes
• Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis
• AVX (News - Alert)-235
• Peptide to Inhibit ETA and ETB for Rapidly Progressive Glomerulonephritis
• GPBP Inhibitors
• Recombinant Enzyme for Immunoglobulin A Nephropathy

For more information visit http://www.researchandmarkets.com/research/mf8g9h/glomerulonephritis

[ Back To TMCnet.com's Homepage ]